Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil Source: Eur Respir J , 49 (3) 1602445; DOI: 10.1183/13993003.02445-2016 Year: 2017
Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia Source: Eur Respir J 2012; 40: 133-142 Year: 2012
Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea Source: Eur Respir J, 57 (3) 2003026; 10.1183/13993003.03026-2020 Year: 2021
Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk Source: Eur Respir J 2012; 39: 1425-1431 Year: 2012
Drug resistant tuberculosis in Odessa, Southern Ukraine: Beijing family strains prevalence and the role of prisons in drug resistant TB transmission Source: Eur Respir J 2006; 28: Suppl. 50, 290s Year: 2006
Treatment outcomes and deaths among multidrug-resistant tuberculosis (MDR-TB) patients in Gomel region, Belarus – 2009-2010 Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Resistance of Mycobacterium tuberculosis to the first-line (MDR) and second line (XDR) anti tuberculosis drugs in the south western zone of Nigeria: A- 3 year retrospective study Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010
The treatment outcomes of isoniazid resistant tuberculosis: Multicenter and retrospective study in South Korea Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis Year: 2010
Efficacy and tolerability of linezolid in the treatment of MDR-TB cases: a TBNET study in Germany and Italy Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008
Outcomes of MDR cases in Iasi county, Romania Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005
Tuberculosis in Estonia: a major impact of Russian MDR Mycobacterium tuberculosis Beijing B0/W148-cluster Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020
Treatment outcome of multi-drug resistant tuberculosis in the Republic of Moldova Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017
Determinants of multidrug-resistant tuberculosis (MDR-TB) in Belarus Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012
A prospective study of multiple drug-resistant tuberculosis in Plovdiv region, Bulgaria, 1989–2004 Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006
Adverse drug reactions to second line anti tuberculosis drugs: A prospective study in Mumbai, India Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Current status of fluoroquinolone use for treatment of tuberculosis in Korea Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Prevalence of fluoroquinolon-resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Our experience with multiple drug-resistant tuberculosis in Plovdiv Region, Bulgaria – 1999–2004 Source: Eur Respir J 2006; 28: Suppl. 50, 379s Year: 2006